Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well pembrolizumab works in combination
with standard therapy in treating patients with glioblastoma. Immunotherapy with monoclonal
antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Drugs used in the
chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors.
Giving pembrolizumab and standard therapy comprising of temozolomide and radiation therapy
may kill tumor cells.